1179149-61-1

Basic information

• Product Name: 2,3-dihydro-2-Methyl-1H-Isoindole-1-carboxylic acid
• Synonyms: 2,3-dihydro-2-Methyl-1H-Isoindole-1-carboxylic acid;2-methylisoindoline-1-carboxylic acid
• CAS NO: 1179149-61-1
• Molecular Formula: C10H11NO2
• Molecular Weight: 177.19984
• Mol File: 1179149-61-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,3-dihydro-2-Methyl-1H-Isoindole-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-2-Methyl-1H-Isoindole-1-carboxylic acid(1179149-61-1)
• EPA Substance Registry System: 2,3-dihydro-2-Methyl-1H-Isoindole-1-carboxylic acid(1179149-61-1)

Safety Data

• Hazardous Substances Data: 1179149-61-1(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 221352-46-1 2-(tert-butoxycarbonyl)isoindoline-1-carboxylic acid 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.